CALDERWOOD & HARKNESS LLP Attorneys at Law
1401 K Street NW, Suite 900 Washington, D.C. 20005 Tel: (202) 555-4100
MONTHLY CLIENT STATUS REPORT
Engagement Reference No.: 1037-00002
ATTORNEY-CLIENT PRIVILEGED AND CONFIDENTIAL This document and its contents are protected by the attorney-client privilege and the work product doctrine. This report is prepared by Calderwood & Harkness LLP for the exclusive use of Solstice Biomedical Inc. and Solstice Biomedical Devices Ltd. and is not intended for distribution to any third party without the prior written authorization of Calderwood & Harkness LLP and the Client.
Report Identification
Right-click to update Table of Contents
Section 1: Executive Summary
This Monthly Client Status Report covers the reporting period of [Month/Year] and provides a comprehensive overview of the current status of Calderwood & Harkness LLP's ("C&H") engagement with Solstice Biomedical Inc. ("SBI") and Solstice Biomedical Devices Ltd. ("SBD," and together with SBI, the "Client") regarding the FDA pre-submission strategy, 510(k) planning, and related regulatory filings for the Solstice Lumina™ Continuous Glucose Monitoring System (the "Lumina CGM System" or the "Device"). The engagement was opened on April 22, 2025, and encompasses the full scope of U.S. regulatory strategy for the Lumina CGM System, which consists of the Lumina C14 implantable sensor and the Lumina R7 wearable reader/transmitter, to be submitted as a traditional 510(k) submission covering both the C14 and R7 as a single integrated system.
During this reporting period, the engagement team [achieved/advanced/continued] the following key activities: [Placeholder for 2–4 sentences describing the most significant accomplishments, decisions, and developments of the period. Examples include: finalization of predicate device analysis; drafting progress on the Pre-Sub meeting package; coordination milestones with third-party consultants; receipt of key engineering deliverables from SBD; completion of regulatory classification analysis; or resolution of strategic questions regarding clinical study design and scope.] These developments represent [meaningful/expected/accelerated] progress toward the milestones set forth in the engagement timeline and reflect the strong collaborative engagement between C&H, the Client's regulatory and engineering teams, and external consultants.
The overall trajectory of the engagement remains [on track / largely on track / subject to the risk factors identified in Section 9] relative to the target regulatory timeline. As previously communicated, the C&H team assessed the Client's original Q1 2026 FDA clearance aspiration as aggressive given the scope of the pre-submission process, anticipated FDA review timelines, and the planned six-month clinical study enrollment period. The revised target timeline, developed in coordination with the Client's regulatory affairs team and Pinnacle Regulatory Consulting Group LLC ("Pinnacle"), contemplates the following key milestones: Pre-Sub meeting request submission to FDA CDRH on June 2, 2025; Pre-Sub meeting package submission on June 16, 2025; Pre-Sub meeting with FDA CDRH, Office of Health Technology 2 — Division of Chemistry and Toxicology Devices ("OHT2-DCT"), on August 14, 2025; biocompatibility testing completion on August 31, 2025; commencement of the LUMINA-US clinical study on September 15, 2025; clinical study completion on March 15, 2026; 510(k) submission on April 30, 2026; target FDA 510(k) clearance in Q3 2026; and target U.S. commercial launch in Q4 2026. This revised timeline provides adequate margin for FDA interactions, potential additional information requests, and anticipated review durations.
[Placeholder for additional paragraph noting any critical developments, decisions requiring Client attention, or changes in risk profile. For example: identification of a new regulatory guidance or enforcement action that may impact the engagement; material updates from coordination with Crestline IP Advisory LLC regarding freedom-to-operate considerations; updates on the clinical study agreement negotiations with Veltrano Clinical Research Organization Inc.; or any matters requiring escalation to Client senior management or the board of directors of SBD.]
Section 2: Engagement Team
The following table sets forth the current composition of the Calderwood & Harkness LLP engagement team assigned to this matter. Any changes to team composition during the reporting period are noted below.
Changes to Team Composition During Reporting Period: [Placeholder — e.g., "No changes to the engagement team composition occurred during this reporting period." Alternatively: "Effective [Date], [Name] joined the engagement team in the capacity of [Role] to provide additional support for [specific workstream]." Or: "[Name] transitioned off the engagement effective [Date] due to [reason]; [his/her] responsibilities have been reassigned to [Name]."]
Section 3: Work Completed During Reporting Period
The following subsections describe in detail the work completed by the Calderwood & Harkness engagement team, in coordination with the Client and third-party consultants, during the reporting period of [Month/Year].
3.1 Regulatory Strategy and Classification
During this reporting period, the engagement team [continued/completed/advanced] the device classification analysis for the Lumina CGM System. The Lumina CGM System is classified as a Class II medical device under FDA product code QKQ, corresponding to the regulation at 21 C.F.R. § 862.1355 (Glucose test system), which covers devices intended for the quantitative measurement of glucose in body fluids. The classification analysis confirms that the Device is eligible for the 510(k) premarket notification pathway, subject to compliance with the applicable special controls for integrated continuous glucose monitoring (iCGM) systems as set forth in the FDA's final order and guidance documents.
The predicate device analysis was [initiated/advanced/finalized] during this period. The C&H team identified the following predicate devices for the substantial equivalence framework:
Primary Predicate: NovaSense GlucoTrack NX-500 (510(k) No. K211034, cleared June 18, 2022). The NX-500 is a real-time continuous glucose monitoring system consisting of an implantable sensor and a wearable receiver/transmitter, cleared under product code QKQ for use by adults (18 years and older) with diabetes mellitus. The NX-500 utilizes an electrochemical enzyme-based sensing technology and is intended for use in making diabetes treatment decisions.
Secondary Predicate: NovaSense GlucoTrack NX-700 (510(k) No. K230489, cleared March 7, 2024). The NX-700 represents an iterative advancement of the NX-500 platform with enhanced Bluetooth Low Energy (BLE) connectivity, an extended 14-day sensor wear period, and an updated algorithm. The NX-700 was cleared for use by adults and pediatric patients (ages 6 years and older) with diabetes mellitus.
The engagement team also [initiated/advanced/completed] the iCGM special controls analysis, examining the Lumina CGM System's compliance with the applicable performance criteria, including MARD targets, consensus error grid zone distributions, alert functionality, and system reliability requirements. A detailed analysis of the substantial equivalence framework — comparing the Lumina CGM System to both the primary and secondary predicate devices across intended use, technological characteristics, and performance — was [drafted/reviewed/finalized] during this period.
Deliverables Completed/Advanced During Reporting Period:
• [Regulatory Classification and Pathway Memorandum (Draft/Final, dated [Date])]
• [Predicate Device Comparison Table (Draft/Final, dated [Date])]
• [iCGM Special Controls Gap Analysis (Draft/Final, dated [Date])]
• [Substantial Equivalence Framework Narrative (Draft/Final, dated [Date])]
3.2 Pre-Submission (Pre-Sub) Activities
The Pre-Submission (Pre-Sub, also referred to as a Q-Sub) process is a critical early step in the engagement. A Pre-Sub meeting request is planned for submission to FDA CDRH on June 2, 2025, with the full Pre-Sub meeting package to follow on June 16, 2025 — sixty (60) calendar days in advance of the target Pre-Sub meeting date of August 14, 2025, consistent with FDA's guidance on the Pre-Submission program ("Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program," FDA Guidance, revised April 2023).
During this reporting period, the engagement team [advanced/completed] the following Pre-Sub meeting package components:
(a) Executive Summary: [Status — e.g., "Initial draft completed and circulated to Client for review on [Date]." / "Revisions incorporated based on Client feedback received [Date]; second draft under C&H review." / "Finalized and approved by Client on [Date]."]
(b) Device Description: [Status — e.g., "Comprehensive device description drafted, incorporating technical specifications for both the Lumina C14 implantable sensor and the Lumina R7 wearable reader/transmitter. Awaiting final engineering drawings and dimensional specifications from SBD engineering team (Dr. Aisling Burke, CTO)."]
(c) Predicate Comparison and Substantial Equivalence Discussion: [Status — e.g., "Draft comparison table and narrative completed. Incorporated feedback from Pinnacle Regulatory Consulting Group LLC. Pending final SBD engineering review of technological characteristics comparison."]
(d) Proposed Performance Testing Plan: [Status — e.g., "Working draft under joint development with Pinnacle (Dr. Sandra Ellison, Thomas Greenbaum). Includes proposed bench testing, analytical performance, and iCGM accuracy studies. Target completion for C&H legal review: [Date]."]
(e) Proposed Clinical Study Protocol Summary: [Status — e.g., "Summary of Protocol SBD-LUM-CL-001 drafted and under review. Coordination with Veltrano CRO (Dr. Lisa Fontaine) ongoing regarding endpoints, statistical analysis plan, and enrollment criteria."]
(f) Questions for FDA: [Status — e.g., "Preliminary list of [number] questions developed in coordination with Client regulatory affairs team and Pinnacle. Questions address predicate acceptance, clinical study design, iCGM performance criteria, and sensor biocompatibility testing expectations. Under C&H partner review."]
C&H coordinated with Pinnacle Regulatory Consulting Group LLC ("Pinnacle"), at 9500 Medical Center Drive, Suite 210, Rockville, MD 20850, during this period. Pinnacle's engagement is led by Dr. Sandra Ellison (Managing Director) and Thomas Greenbaum (Senior Regulatory Specialist), who are responsible for providing technical summaries, performance testing protocol development, and regulatory science support in coordination with C&H's legal strategy oversight. [Status of Pinnacle coordination — e.g., "Biweekly coordination calls with Pinnacle were held on [Dates]. Key outputs received from Pinnacle during this period included [description of deliverables]. Outstanding items from Pinnacle include [description]."]
3.3 Clinical and Testing Strategy
IDE Exemption Analysis
The engagement team [initiated/advanced/completed] the analysis of investigational device exemption (IDE) requirements for the planned LUMINA-US clinical study. Based on our review, the Lumina CGM System qualifies as a non-significant risk (NSR) device under 21 C.F.R. § 812.2(c)(3) for purposes of the LUMINA-US study (Protocol SBD-LUM-CL-001). The NSR determination is based on the following factors: (i) the Device is not an implant that presents a potential for serious risk to the health, safety, or welfare of a subject (the C14 sensor is subcutaneously inserted for a limited 14-day wear period, consistent with the cleared predicate devices); (ii) the Device is not intended for use in supporting or sustaining human life; (iii) the Device does not present a potential for serious risk to the health, safety, or welfare of a subject; and (iv) the Device is not otherwise significant risk. Under the NSR pathway, an abbreviated IDE applies, and the study may proceed under IRB approval without the need for a separate IDE application to FDA. The C&H team has prepared [a draft/a final] memorandum documenting this analysis for the Client's records.
Clinical Study Agreement — Veltrano CRO
The clinical study is planned to be conducted by Veltrano Clinical Research Organization Inc. ("Veltrano CRO"), located at 500 North Capitol Street, Suite 700, Indianapolis, IN 46204, under the direction of Dr. Lisa Fontaine, VP of Clinical Operations. The clinical study agreement between SBI and Veltrano CRO [is currently under negotiation/has been reviewed by C&H and comments provided/is in final form pending execution]. The study envisions enrollment of three hundred fifty (350) subjects across six (6) U.S. clinical sites, at a per-subject cost of $12,000, for a total clinical study budget of $4,200,000. Key contractual provisions under review include indemnification, limitation of liability, data ownership, publication rights, regulatory compliance obligations, and termination provisions. [Status — e.g., "C&H provided a redline of the Veltrano CRO master services agreement and clinical study work order on [Date]. Outstanding negotiation points include [description]. A follow-up call between C&H, SBI, and Veltrano CRO is scheduled for [Date]."]
IRB Submission — Clearwater Institutional Review Board LLC
The IRB submission for Protocol SBD-LUM-CL-001 is planned for submission to Clearwater Institutional Review Board LLC ("Clearwater IRB"), IRB Registration No. IRB-2019-04821, located at 3200 Bayshore Boulevard, Tampa, FL 33629. [Status — e.g., "Clearwater IRB submission package is under preparation. Target submission date is [Date]. The submission package includes the study protocol, investigator's brochure, informed consent form, and case report forms."]
Informed Consent Form
The informed consent form ("ICF") for the LUMINA-US study was [drafted by Veltrano CRO / received from Client] and is [currently under C&H review and markup / has been reviewed by C&H with comments provided on [Date]]. C&H's review focuses on compliance with 21 C.F.R. Part 50 (Protection of Human Subjects), 21 C.F.R. Part 56 (Institutional Review Boards), and applicable FDA guidance on informed consent for medical device clinical studies. Key areas of review include risk disclosure language, compensation provisions, data privacy disclosures (including HIPAA authorization), and sponsor contact information. [Status — e.g., "C&H provided a marked-up ICF to the Client on [Date]. [Number] substantive comments were included. Client review and response are pending."]
Biocompatibility Testing — Whitmore Laboratories Inc.
Biocompatibility testing for the Lumina CGM System is being conducted by Whitmore Laboratories Inc. ("Whitmore"), located at 1625 Shady Grove Road, Suite 300, Gaithersburg, MD 20878, under the direction of Dr. James Haverford, Director of Biocompatibility Testing. Whitmore holds A2LA Certificate No. 3847.01 and maintains ISO 17025 and GLP accreditation relevant to the testing program. The biocompatibility testing program encompasses the full suite of ISO 10993 biological evaluation testing required for the Lumina C14 implantable sensor, including cytotoxicity, sensitization, irritation, acute systemic toxicity, subchronic toxicity, genotoxicity, and implantation studies. The testing budget is $485,000 for biocompatibility testing and $175,000 for electromagnetic compatibility (EMC) and electrical safety testing, for a combined total of $660,000. The target completion date for all biocompatibility testing is August 31, 2025.
[Status — e.g., "C&H reviewed and commented on the Whitmore testing protocol on [Date]. Testing program [has been initiated / is scheduled to begin on [Date]]. Preliminary cytotoxicity testing results [are expected by [Date] / were received on [Date] and are under review]. No issues have been identified to date. Monthly status updates from Whitmore are received by the C&H team and the Client's QA Director, Fiona Drennan."]
3.4 Software and Cybersecurity Documentation
Software Documentation Gap Analysis
The Lumina CGM System includes multiple software components that are subject to FDA's software review requirements. The C&H team [initiated/advanced/completed] a software documentation gap analysis during this reporting period, evaluating the current state of the Client's software documentation against the requirements for a 510(k) submission. The software level of concern for the Lumina CGM System has been preliminarily assessed as Major, reflecting the Device's role in providing glucose measurements that may be used to inform diabetes treatment decisions. The analysis evaluated compliance with IEC 62304:2006/A1:2015 (Medical device software — Software life cycle processes) and FDA guidance documents on software validation and premarket submissions.
The following software components are under review:
• Lumina Firmware v3.4.2 — embedded firmware for the C14 implantable sensor, controlling electrochemical measurement, data sampling, and BLE transmission functions
• Lumina Reader OS v2.1.0 — operating system and application software for the R7 wearable reader/transmitter, responsible for sensor data reception, processing, display, and alert generation
• LuminaPredict Algorithm v2.1 — proprietary glucose prediction and trend analysis algorithm integrated within the R7 reader software
• Lumina Mobile App v1.0.3 — companion iOS/Android mobile application for data visualization, historical trend analysis, and remote monitoring/sharing functionality
[Status — e.g., "Preliminary gap analysis identified [number] documentation gaps, primarily in the areas of software requirements specification, software architecture documentation, software verification and validation protocols, and traceability matrices. A detailed gap analysis report was provided to the Client's CTO, Dr. Aisling Burke, on [Date], with recommendations for remediation. The Client's software engineering team has acknowledged receipt and is working to address identified gaps. Target completion for all software documentation remediation: [Date]."]
Cybersecurity Premarket Submission
The C&H team [initiated/advanced/completed] the review of the Client's cybersecurity documentation against the FDA's guidance, "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions" (September 2023). The cybersecurity premarket submission checklist is being developed to ensure inclusion of all required elements, including threat modeling (STRIDE methodology), cybersecurity risk assessment, software bill of materials (SBOM), security architecture documentation, vulnerability management plan, and patch/update mechanisms.
[Status — e.g., "The STRIDE threat model for the Lumina CGM System was [received from the Client's engineering team / is under development by the Client's engineering team with C&H input]. The software bill of materials (SBOM) has been [requested from the Client / received in draft form / reviewed by C&H]. C&H provided comments on the cybersecurity risk assessment on [Date]. Outstanding items include [description]."]
3.5 510(k) Submission Preparation
Although the 510(k) submission target date is April 30, 2026, preliminary preparation of certain submission components has commenced during this period to ensure readiness and to identify any documentation gaps as early as possible. The following components are in various stages of preparation:
(a) 510(k) Cover Letter: [Status — e.g., "Template drafted; will be finalized upon completion of all supporting documentation."]
(b) 510(k) Summary (per 21 C.F.R. § 807.92): [Status — e.g., "Preliminary outline drafted, incorporating Device description, intended use, predicate comparison summary, and performance data summary. Will be updated as testing and clinical data become available."]
(c) Indications for Use Statement (FDA Form 3881): [Status — e.g., "Draft indications for use statement prepared and circulated to Client for review on [Date]. The proposed indications for use are modeled on the primary predicate's cleared indications, with modifications to reflect the Lumina CGM System's specific features and claims. Pending Client approval."]
(d) Substantial Equivalence Comparison Table: [Status — e.g., "Detailed side-by-side comparison table under development, comparing the Lumina CGM System to both the primary predicate (K211034) and secondary predicate (K230489) across intended use, device design, materials, performance characteristics, and software/algorithm functionality. Draft table is [percentage]% complete."]
Labeling Review. C&H [initiated/advanced] the review of the Client's proposed labeling for the Lumina CGM System, including the package insert (Instructions for Use), quick start guide, and carton/box labeling. The review evaluates compliance with 21 C.F.R. Part 801 (Labeling), including general device labeling requirements, adequate directions for use, and any applicable special requirements for iCGM devices. [Status — e.g., "Draft labeling materials were received from the Client on [Date]. C&H's review is in progress. Preliminary comments have been provided on [number] of [number] labeling components. Outstanding items include review of the patient-facing quick start guide and evaluation of specific claims for compliance with the substantial equivalence framework."]
Promotional Claims Guidance
C&H [prepared/is preparing] a guidance memorandum for the Client regarding permissible promotional claims for the Lumina CGM System in the U.S. market, both pre-clearance and post-clearance. The memorandum addresses FDA's enforcement position on promotional activities for uncleared devices, restrictions on off-label promotion, and best practices for marketing communications. [Status — e.g., "Draft memorandum is under preparation. Target delivery: [Date]."]
3.6 IP and Freedom-to-Operate Matters
C&H continues to coordinate with Crestline IP Advisory LLC ("Crestline"), located at 75 Federal Street, Suite 1800, Boston, MA 02110, under the direction of Dr. Raymond Cho (Patent Attorney), regarding the freedom-to-operate ("FTO") analysis for the Lumina CGM System in the U.S. market. The FTO analysis is focused on the NovaSense patent portfolio, which includes the following U.S. patents of relevance:
Crestline's preliminary assessment, based on an initial review of the patent claims and the Lumina CGM System's technical specifications, characterizes the FTO risk as follows:
• U.S. 10,847,221 — Risk: Low-to-Moderate. This patent covers a multi-layer enzyme-based electrode coating architecture. Crestline has identified structural similarities between certain claims of this patent and SBD's proprietary PtIr-4G electrode coating technology utilized in the Lumina C14 sensor. A full claim chart analysis is [in progress / under review / completed (see Deliverable Log entry)].
• U.S. 11,234,567 — Risk: Low. This patent covers an adaptive calibration algorithm. Preliminary analysis suggests that the LuminaPredict Algorithm v2.1 employs a sufficiently distinct calibration methodology. [Status of detailed analysis.]
• U.S. 11,502,893 — Risk: Low. This patent covers a miniaturized sensor architecture with specific signal processing and BLE communication features. Preliminary analysis suggests limited overlap with the Lumina C14 sensor's design. [Status of detailed analysis.]
Design-Around Status: In response to the low-to-moderate risk identified for U.S. Patent No. 10,847,221, the SBD engineering team (Dr. Aisling Burke, CTO) has been developing an alternative electrode deposition process designed to avoid potential infringement of the identified claims. Crestline is [currently reviewing / has reviewed] the proposed design-around for its effectiveness in differentiating the Lumina CGM System from the patent claims at issue. [Status — e.g., "Crestline provided preliminary feedback on the design-around on [Date]. Additional engineering specifications have been requested from the SBD team. A follow-up review is scheduled for [Date]."]
NovaSense: NovaSense is headquartered at 4800 Innovation Parkway, San Diego, CA 92121, and is represented by Marlowe Asset Management Patent Group LLP (Patricia Langford). As of the date of this report, there is no formal dispute, demand, or litigation between SBD/SBI and NovaSense regarding the above-referenced patents or any other intellectual property matter. C&H and Crestline continue to monitor the situation and advise the Client on risk mitigation strategies.
3.7 Establishment Registration and Other Administrative Matters
Establishment Registration and Device Listing
C&H [prepared/is preparing] a memorandum advising SBI on its obligations under 21 C.F.R. Part 807 regarding establishment registration and device listing with FDA. SBI, as the initial distributor and U.S. agent for the Lumina CGM System, is required to register its establishment and list the Device with FDA prior to commercial distribution. [Status — e.g., "Draft memorandum was provided to the Client on [Date]. The memorandum addresses registration timing, listing requirements, annual renewal obligations, and the relationship between SBI's establishment registration and SBD's foreign manufacturer registration."]
MDUFA Small Business Qualification Analysis
C&H has completed the analysis of SBI's eligibility for the Medical Device User Fee Amendments (MDUFA) small business qualification. Under MDUFA, a small business is defined as a business with gross receipts or sales of no more than $100 million, taking into account the receipts of all affiliates. Although SBI's standalone U.S. subsidiary revenue is approximately $22.8 million, the consolidated global revenue of the parent entity, Solstice Biomedical Devices Ltd., is approximately €187.4 million (approximately $204.3 million at a conversion rate of €1 = $1.09), which exceeds the applicable threshold. Accordingly, SBI does not qualify for the MDUFA small business reduced fee, and the standard FY2025 510(k) premarket notification review fee of $22,417 will apply at the time of submission.
Post-Clearance Regulatory Obligations Memorandum
C&H [is preparing/has completed] a comprehensive memorandum for the Client addressing post-clearance regulatory obligations, including medical device reporting (MDR) requirements under 21 C.F.R. Part 803, correction and removal reporting under 21 C.F.R. Part 806, Quality System Regulation (QSR) compliance under 21 C.F.R. Part 820, and post-market surveillance obligations. [Status — e.g., "This memorandum is scheduled for delivery in [Month/Year], in advance of the anticipated clearance date, to allow the Client adequate time to implement necessary post-market systems and procedures."]
3.8 Coordination and Privilege Management
Coordination Protocol. C&H maintains a structured coordination protocol with all third-party consultants and service providers engaged in connection with this matter. The protocol establishes regular communication cadences, document sharing procedures, and review workflows to ensure efficient progress across all workstreams. During this reporting period, coordination activities included [description of coordination calls, meetings, document exchanges, and other interactions with Pinnacle, Crestline, Whitmore, Veltrano CRO, and/or Clearwater IRB].
Privilege and Work Product Protection
C&H has implemented privilege and work product protection guidelines applicable to all communications and documents generated in connection with this engagement. These guidelines were communicated to the Client and to all third-party consultants, and include protocols for marking privileged communications, limiting distribution of privileged materials, and ensuring that third-party consultants engaged at the direction of counsel operate within the scope of the common interest and/or Kovel doctrine protections. [Status — e.g., "Privilege guidelines were distributed to all engagement participants on [Date]. No privilege issues have been identified during this reporting period."]
EU MDR Coordination — Hargrove & Endicott LLP
C&H continues to coordinate with Hargrove & Endicott LLP ("H&E"), located at 38 Fitzwilliam Square East, Dublin D02 NH85, Ireland (Ciara Brennan, Partner), regarding the interface between the Client's EU Medical Device Regulation (EU MDR 2017/745) compliance program and the FDA regulatory strategy for the Lumina CGM System. The Lumina CGM System holds an EU MDR CE certificate, MCA-2024-07319, issued September 12, 2024, by Meridian Conformity Assessment GmbH (Notified Body No. 0483, Dr. Henrik Vogt, Lead Auditor), based in Berlin, Germany. Coordination between C&H and H&E ensures that FDA submission documentation and EU MDR technical documentation are aligned where applicable, and that regulatory strategies in both jurisdictions do not create unnecessary inconsistencies. [Status — e.g., "C&H and H&E participated in a joint coordination call on [Date] to discuss harmonization of clinical evidence requirements and labeling standards. No conflicts between the EU and U.S. regulatory strategies have been identified."]
Section 4: Regulatory Milestone Tracker
The following table tracks all key regulatory milestones for the Lumina CGM System U.S. regulatory program. Status designations are as follows: Completed (milestone achieved), On Track (milestone expected to be achieved by target date), At Risk (milestone may be delayed; monitoring required), Delayed (milestone will not be achieved by target date; revised date indicated).
Critical Path and Dependencies:
The following dependencies define the critical path for the regulatory program and should be closely monitored:
• Pre-Sub meeting feedback from FDA (Milestone 4) is expected to inform and potentially modify the clinical study design, performance testing requirements, and predicate acceptance. Any material changes to the regulatory strategy resulting from the Pre-Sub meeting may impact downstream milestones.
• Biocompatibility testing completion (Milestone 5) is a prerequisite for inclusion of biocompatibility data in the 510(k) submission. Delays in testing completion will directly impact the 510(k) submission date.
• Clinical study completion (Milestone 8) is on the critical path. The clinical study data package, including the final clinical study report, must be complete prior to 510(k) submission. The six-month study duration, from September 15, 2025 through March 15, 2026, allows approximately six (6) weeks between study completion and the target 510(k) submission date (April 30, 2026) for data analysis, report preparation, and final submission assembly.
• The Atlas Underwriting Partners insurance policy (Milestone 7) expires September 30, 2025, during the anticipated clinical study period. Timely renewal is essential to avoid a coverage gap that could affect clinical study operations and contractual obligations.
Section 5: Open Issues and Action Items
The following table identifies open issues and action items requiring attention. Items are tracked from period to period until closed.
Section 6: Budget and Financial Tracking
6.1 Calderwood & Harkness Legal Fees
The following table tracks Calderwood & Harkness legal fees incurred during the reporting period and cumulatively to date, measured against the total engagement fee estimate of $650,000. This estimate was provided in C&H's engagement letter dated April 22, 2025, and is based on the assumed scope of work, regulatory pathway, and timeline described therein. The estimate is not a cap or fixed fee; actual fees may vary based on the complexity of matters encountered, changes in scope, regulatory developments, and other factors. C&H will promptly notify the Client if it appears that actual fees may materially exceed the estimate.
Retainer Status: A retainer in the amount of $75,000 was received from the Client on April 28, 2025, in accordance with the terms of the engagement letter. The retainer is held in C&H's client trust account and is applied against outstanding invoices as follows:
Billing Frequency: C&H invoices the Client on a monthly basis. Invoices are due within thirty (30) days of the invoice date.
Billing Variances / Anticipated Overruns: [Placeholder — e.g., "No material billing variances have been identified during this reporting period. Current spending is consistent with the engagement estimate, and no overrun is anticipated at this time." Or: "Due to [specific factor], the engagement team has identified a potential for fees in excess of the original estimate. C&H anticipates that the total engagement fees may reach approximately $[Amount], representing an increase of approximately $[Amount] ([Percentage]%) over the original estimate. C&H will discuss this matter with the Client at the next scheduled call on [Date]."]
6.2 Disbursements
The following table tracks disbursements incurred by C&H in connection with this engagement. Pursuant to the engagement letter, individual disbursements in excess of $15,000 require prior Client approval.
6.3 Total External Regulatory Cost Tracker
The following summary table tracks all estimated external costs associated with the Lumina CGM System U.S. regulatory program, including C&H legal fees, regulatory consulting fees, testing costs, clinical study costs, and FDA user fees.
[Note: The above estimates are based on current scope assumptions and are subject to change based on FDA feedback, clinical study modifications, and other factors. C&H will update this tracker monthly to reflect actual expenditures and any revised estimates.]
Section 7: Key Client and Third-Party Contacts
The following table provides a reference list of key contacts for the engagement.
Solstice Biomedical Devices Ltd. (Ireland — Parent Entity)
Solstice Biomedical Inc. (U.S. — Subsidiary)
Pinnacle Regulatory Consulting Group LLC
Crestline IP Advisory LLC
Whitmore Laboratories Inc.
Veltrano Clinical Research Organization Inc.
Clearwater Institutional Review Board LLC
Hargrove & Endicott LLP (EU MDR Counsel)
Meridian Conformity Assessment GmbH (EU Notified Body)
Atlas Underwriting Partners Ltd. (Product Liability Insurance)
Broadleaf Accounting Partners LLP
Section 8: Next Steps and Upcoming Priorities
The following priorities and planned activities are identified for the next reporting period, [Month/Year]:
1. Pre-Sub Meeting Request Submission. [If applicable — e.g., "Finalize and submit the Pre-Sub (Q-Sub) meeting request letter to FDA CDRH by June 2, 2025. The request will identify the proposed meeting date (August 14, 2025), meeting type (written feedback meeting or in-person/teleconference meeting, as appropriate), and the subject matter of the Pre-Sub."]
2. Pre-Sub Meeting Package Finalization and Submission. [If applicable — e.g., "Complete all Pre-Sub meeting package components and submit the full package to FDA by June 16, 2025 (60 days in advance of the proposed meeting date). This requires timely receipt of outstanding engineering deliverables from SBD, including final device description specifications, bench testing summaries, and software documentation."]
3. Clinical Study Agreement Execution. [If applicable — e.g., "Finalize negotiation of the clinical study agreement with Veltrano CRO and execute the agreement. Resolution of outstanding contractual terms (indemnification, data ownership) is required prior to execution."]
4. IRB Submission. [If applicable — e.g., "Submit the complete IRB submission package to Clearwater IRB, including Protocol SBD-LUM-CL-001, investigator's brochure, informed consent form, and supporting documents."]
5. Biocompatibility Testing Monitoring. [If applicable — e.g., "Continue monitoring Whitmore Laboratories' biocompatibility testing program. Review interim test results as they become available. Escalate any testing anomalies or failures immediately."]
6. FTO Analysis Completion. [If applicable — e.g., "Receive and review Crestline's completed claim chart analysis for U.S. Patent No. 10,847,221. Evaluate the adequacy of SBD's proposed design-around. Provide updated FTO risk assessment to the Client."]
7. Software and Cybersecurity Documentation Remediation. [If applicable — e.g., "Continue coordination with SBD engineering team on software documentation gap remediation. Review and comment on updated software documentation deliverables. Advance cybersecurity premarket submission checklist completion."]
8. Insurance Renewal. [If applicable — e.g., "Initiate the renewal process for the Atlas Underwriting Partners product liability insurance policy (Policy No. AUP-PL-2024-00893, expiring September 30, 2025). Ensure that renewed coverage is adequate for clinical study operations and anticipated U.S. commercial launch activities."]
Decisions and Inputs Needed from the Client:
• [Description of specific decisions or inputs required from Client personnel — e.g., "Approval of the final Pre-Sub meeting package components, including the proposed Questions for FDA." / "Confirmation of final sensor functional specifications." / "Authorization to proceed with IRB submission."]
• [Additional decision/input items as applicable.]
Anticipated C&H Deliverables:
• [List of documents, memoranda, and other deliverables that C&H expects to complete and deliver during the next reporting period.]
Scheduled Coordination Meetings:
• [List of coordination meetings scheduled during the next period, including participants, date/time, and subject matter. For example: "Biweekly C&H-Pinnacle coordination call, [Dates]." / "C&H-Client regulatory strategy review meeting, [Date]." / "C&H-Crestline FTO review call, [Date]." / "C&H-Veltrano CRO clinical study agreement negotiation call, [Date]."]
Section 9: Risk Register
The following table identifies key risks to the Lumina CGM System U.S. regulatory program and the associated mitigation strategies. Risks are assessed based on their likelihood and potential impact on the program timeline, budget, and/or regulatory outcome. The risk register is updated monthly to reflect changes in risk profile.
Appendix A: Glossary of Key Terms and Acronyms
Appendix B: Document / Deliverable Log
The following table provides a running log of all documents and deliverables produced by Calderwood & Harkness LLP and other engagement participants during the course of the engagement. This log is updated monthly and tracks deliverables across all phases of the engagement.
This log is maintained by Calderwood & Harkness LLP and is updated with each Monthly Client Status Report. Deliverables are numbered sequentially. Documents marked "Draft" are subject to further revision. All documents are subject to the attorney-client privilege and/or work product doctrine unless otherwise noted.
END OF MONTHLY CLIENT STATUS REPORT
Report No. [Sequential Number] — [Month/Year]
Engagement Reference No.: 1037-00002
CONFIDENTIALITY NOTICE
This report is privileged and confidential, prepared by Calderwood & Harkness LLP for the exclusive use of Solstice Biomedical Inc. and Solstice Biomedical Devices Ltd. This document and its contents are protected by the attorney-client privilege and the work product doctrine. Do not distribute, copy, or disclose this report or any portion thereof to any third party without the prior written authorization of Calderwood & Harkness LLP. If you have received this document in error, please notify Calderwood & Harkness LLP immediately at (202) 555-4100 and destroy all copies.
| Calderwood & Harkness LLP | 1401 K Street NW, Suite 900 | Washington, D.C. 20005 Engagement Reference No.: 1037-00002 | ||
| Field | Details | |||
| Client: | Solstice Biomedical Inc. (a Delaware corporation, File No. 7834291), 220 Westbrook Drive, Suite 400, Cambridge, MA 02142 | |||
| Parent Entity: | Solstice Biomedical Devices Ltd. (Ireland, CRO No. 648231), Unit 14, Liffey Innovation Park, Chapelizod, Dublin D20 FX72, Ireland | |||
| Matter: | FDA Pre-Submission and 510(k) Regulatory Strategy — Solstice Lumina™ CGM System | |||
| Reporting Period: | [Month/Year] | |||
| Report Date: | [Date] | |||
| Report No.: | [Sequential Number] | |||
| Prepared By: | [Attorney Name(s)], Calderwood & Harkness LLP | |||
| Distributed To: | Dr. Niamh Tierney, VP of Regulatory Affairs, Solstice Biomedical Devices Ltd.; Marcus Hale, VP of U.S. Operations, Solstice Biomedical Inc.; [Additional Recipients as Designated by Client] | |||
| CC: | Miriam Calloway, Responsible Partner, Calderwood & Harkness LLP; Joel Strauss, Billing Partner, Calderwood & Harkness LLP | |||
| Name | Role | Experience / Background | Contact | |
| Miriam Calloway | Responsible Partner, Healthcare & Life Sciences Practice Group | 22 years of FDA regulatory law experience; former senior counsel at FDA Center for Devices and Radiological Health (CDRH), Office of Device Evaluation; extensive experience advising medical device manufacturers on 510(k), PMA, De Novo, and IDE submissions; admitted in the District of Columbia and Maryland | mcalloway@calderwoodharkness.com; (202) 555-4112 | |
| Joel Strauss | Billing Partner, Healthcare & Life Sciences Practice Group | 18 years of experience in healthcare regulatory, transactional, and compliance matters; lead billing partner for multiple medical device and life sciences engagements; admitted in the District of Columbia and New York | jstrauss@calderwoodharkness.com; (202) 555-4118 | |
| Amy Whitfield | Lead Associate, Healthcare & Life Sciences Practice Group | 6 years of experience in FDA regulatory law with a focus on 510(k) and PMA submissions for Class II and Class III medical devices, including in vitro diagnostics and digital health devices; prior experience at a leading medical device manufacturer's in-house regulatory department; admitted in the District of Columbia and Virginia | awhitfield@calderwoodharkness.com; (202) 555-4134 | |
| Sean Morrissey | Working Associate, Healthcare & Life Sciences Practice Group | 3 years of experience in FDA regulatory law with a focus on pre-submission strategy, device classification analysis, and regulatory pathway assessment; M.S. in Biomedical Engineering from Johns Hopkins University; admitted in the District of Columbia and Maryland | smorrissey@calderwoodharkness.com; (202) 555-4141 | |
| Patent No. | Issue Date | Expiration Date | Title/Subject Matter | |
| U.S. 10,847,221 | December 1, 2020 | November 14, 2037 | Enzyme-based electrochemical sensor with multi-layer electrode coating architecture | |
| U.S. 11,234,567 | January 25, 2022 | March 22, 2039 | Wireless continuous glucose monitoring system with adaptive calibration algorithm | |
| U.S. 11,502,893 | November 15, 2022 | June 8, 2040 | Miniaturized implantable sensor with integrated signal processing and BLE communication | |
| No. | Milestone | Target Date | Status | Comments |
| 1 | Engagement opened | April 22, 2025 | Completed | Engagement letter executed April 22, 2025; retainer received April 28, 2025. |
| 2 | Pre-Sub (Q-Sub) meeting request submitted to FDA CDRH | June 2, 2025 | [On Track / At Risk / Completed] | [Comments — e.g., "Request letter drafted; under final partner review." / "Submitted on [Date]; FDA acknowledgment received [Date]."] |
| 3 | Pre-Sub meeting package submitted to FDA (60 days before meeting) | June 16, 2025 | [On Track / At Risk / Completed] | [Comments — e.g., "Package components in various stages of completion; see Section 3.2 for detail."] |
| 4 | Pre-Sub meeting with FDA CDRH (OHT2 — Division of Chemistry and Toxicology Devices) | August 14, 2025 | [On Track / At Risk] | [Comments — e.g., "Meeting date subject to FDA scheduling confirmation following Pre-Sub request submission."] |
| 5 | Biocompatibility testing complete (Whitmore Laboratories Inc.) | August 31, 2025 | [On Track / At Risk] | [Comments — e.g., "Testing program initiated; on track for completion. See Section 3.3 for detail."] | ||
| 6 | LUMINA-US clinical study commenced (Veltrano CRO; 6 U.S. clinical sites; 350 subjects; Protocol SBD-LUM-CL-001) | September 15, 2025 | [On Track / At Risk] | [Comments — e.g., "Dependent on IRB approval, clinical site agreements, and CRO agreement finalization."] | ||
| 7 | Atlas Underwriting Partners Ltd. product liability insurance policy expiration (Policy No. AUP-PL-2024-00893; $25M per occurrence / $50M aggregate) | September 30, 2025 | [Action Required] | [Comments — e.g., "Policy expiration falls during planned clinical study period. Renewal process must be initiated no later than [Date] to avoid coverage gap. See Section 5 for action item."] | ||
| 8 | LUMINA-US clinical study completed | March 15, 2026 | [On Track / At Risk] | [Comments — e.g., "On critical path. Study duration estimated at 6 months from commencement."] | ||
| 9 | 510(k) submission to FDA | April 30, 2026 | [On Track / At Risk] | [Comments — e.g., "Dependent on completion of clinical study, biocompatibility testing, and all 510(k) package components."] | ||
| 10 | Target FDA 510(k) clearance (estimated 90-day review period + potential additional information request) | Q3 2026 | [On Track / At Risk] | [Comments — e.g., "Assumes 90-day statutory review period; may be extended if FDA issues additional information (AI) request."] | ||
| 11 | Target U.S. commercial launch | Q4 2026 | [On Track / At Risk] | [Comments — e.g., "Dependent on FDA clearance, establishment registration/listing, labeling finalization, and commercial readiness."] | ||
| Item No. | Description | Responsible Party | Due Date | Priority | Status | |
| 5.1 | Finalization of Pre-Sub meeting package components (Executive Summary, Device Description, Predicate Comparison, Proposed Performance Testing Plan, Proposed Clinical Study Protocol Summary, Questions for FDA) | C&H (Whitfield, Morrissey); Pinnacle (Ellison, Greenbaum); SBD Engineering (Dr. Burke, CTO; Drennan, QA Director) | [Date — aligned with June 16, 2025 submission target] | High | [Open / In Progress] | |
| 5.2 | Completion of Crestline FTO claim chart analysis for U.S. Patent No. 10,847,221 and review of SBD design-around proposal for alternative electrode deposition process | Crestline (Dr. Cho); SBD Engineering (Dr. Burke) | [Date] | High | [Open / In Progress] | |
| 5.3 | IRB protocol and informed consent form submission to Clearwater Institutional Review Board LLC (IRB Reg. No. IRB-2019-04821) for Protocol SBD-LUM-CL-001 | C&H (Whitfield); Veltrano CRO (Dr. Fontaine); SBI (Hale) | [Date — to support September 15, 2025 study commencement] | High | [Open / In Progress] | |
| 5.4 | Whitmore Laboratories biocompatibility testing program initiation and ongoing monitoring; receipt and review of interim testing results | Whitmore (Dr. Haverford); C&H (Morrissey); SBD QA (Drennan) | Ongoing through August 31, 2025 | High | [Open / In Progress] | |
| 5.5 | Atlas Underwriting Partners product liability insurance policy renewal planning (Policy No. AUP-PL-2024-00893; $25M per occurrence / $50M aggregate; expires September 30, 2025). Current coverage includes U.S. market entry activities and clinical trial operations. Renewal must be completed prior to expiration to avoid coverage gap during clinical study. | SBI (Hale); SBD (Dr. Tierney); Broadleaf Accounting Partners LLP (Murray) | Renewal process to be initiated no later than [Date — e.g., August 1, 2025] | High | [Open] | |
| 5.6 | Solstice engineering team deliverables: software documentation remediation, cybersecurity SBOM preparation, bench testing data packages (analytical performance, sensor stability, reagent stability, shelf life) | SBD Engineering (Dr. Burke); SBD QA (Drennan) | [Various dates per deliverable schedule] | High | [Open / In Progress] | |
| 5.7 | MARD target validation data package: demonstration that the Lumina CGM System achieves a mean absolute relative difference (MARD) of ≤ 9.0% in clinical testing. Consensus error grid analysis to demonstrate ≥ 99% of paired data points fall within Zones A and B. | SBD Engineering (Dr. Burke); Pinnacle (Ellison); Veltrano CRO (Dr. Fontaine) | Upon clinical study completion (March 15, 2026) | Medium | [Open] | |
| 5.8 | Confirmation of final sensor functional specifications for the Lumina C14 implantable sensor: sensor functional life of 336 hours (14 days); measurement range of 40–400 mg/dL; warm-up period ≤ 60 minutes; alert latency ≤ 5 minutes. Any deviations from these specifications may impact the predicate comparison and clinical study design. | SBD Engineering (Dr. Burke) | [Date] | Medium | [Open / In Progress] | |
| 5.9 | Finalization of clinical study agreement with Veltrano Clinical Research Organization Inc.; resolution of outstanding negotiation points on indemnification and data ownership | C&H (Whitfield); SBI (Hale); Veltrano CRO (Dr. Fontaine) | [Date] | High | [Open / In Progress] | |
| 5.10 | [Placeholder for additional action items as they arise during each reporting period] | [Party] | [Date] | [Priority] | [Status] | |
| Timekeeper | Role | Hourly Rate | Hours This Period | Fees This Period | Cumulative Hours | Cumulative Fees |
| Miriam Calloway | Responsible Partner | $1,150/hr | [Hours] | $[Amount] | [Hours] | $[Amount] |
| Joel Strauss | Billing Partner | $1,050/hr | [Hours] | $[Amount] | [Hours] | $[Amount] |
| Amy Whitfield | Lead Associate | $625/hr | [Hours] | $[Amount] | [Hours] | $[Amount] |
| Sean Morrissey | Working Associate | $475/hr | [Hours] | $[Amount] | [Hours] | $[Amount] |
| TOTAL | [Hours] | $[Amount] | [Hours] | $[Amount] | ||
| Summary Metric | Value |
| Total fees this reporting period: | $[Amount] | |||
| Cumulative total fees to date: | $[Amount] | |||
| Total engagement fee estimate: | $650,000 | |||
| Remaining budget (estimate less cumulative): | $[Amount] | |||
| Percentage of estimate utilized: | [Percentage]% | |||
| Blended effective rate this period: | $[Amount]/hr | |||
| Blended effective rate cumulative: | $[Amount]/hr (estimated ~$725/hr) | |||
| Retainer Item | Amount | |||
| Retainer received (April 28, 2025): | $75,000 | |||
| Amount applied to invoices to date: | $[Amount] | |||
| Remaining retainer balance: | $[Amount] | |||
| Category | This Period | Cumulative to Date | ||
| Filing fees | $[Amount] | $[Amount] | ||
| Travel (air, ground, lodging, meals) | $[Amount] | $[Amount] | ||
| Document production / copying | $[Amount] | $[Amount] | ||
| Research databases (Westmark Data Systems, Sundial Solutions) | $[Amount] | $[Amount] | ||
| Courier / overnight delivery | $[Amount] | $[Amount] | ||
| Other | $[Amount] | $[Amount] | ||
| TOTAL DISBURSEMENTS | $[Amount] | $[Amount] | ||
| Disbursement Summary | Amount | |||
| Cumulative disbursements to date: | $[Amount] | |||
| Prior approval threshold: | $15,000 per individual disbursement | |||
| Any disbursements exceeding threshold: | [Yes/No — if yes, describe and note approval status] | |||
| Budget Item | Estimated Cost | Committed / Invoiced to Date | Remaining | Variance Notes |
| FDA 510(k) user fee (FY2025 standard) | $22,417 | $[Amount] | $[Amount] | [Not yet due; payable upon 510(k) submission] |
| Biocompatibility testing (Whitmore Laboratories Inc.) | $485,000 | $[Amount] | $[Amount] | [Status notes] |
| EMC / electrical safety testing (Whitmore Laboratories Inc.) | $175,000 | $[Amount] | $[Amount] | [Status notes] |
| Clinical study (Veltrano CRO; 350 subjects × $12,000) | $4,200,000 | $[Amount] | $[Amount] | [Status notes] |
| Pinnacle Regulatory Consulting Group LLC fees | $380,000 | $[Amount] | $[Amount] | [Status notes] |
| Crestline IP Advisory LLC FTO analysis fees | $215,000 | $[Amount] | $[Amount] | [Status notes] |
| Calderwood & Harkness LLP legal fees | $650,000 | $[Amount] | $[Amount] | [Status notes; see Section 6.1] |
| TOTAL ESTIMATED EXTERNAL REGULATORY COSTS | $6,127,417 | $[Amount] | $[Amount] | |
| Name | Title | Location | Contact | |
| Dr. Eoin Gallagher | Chief Executive Officer | Unit 14, Liffey Innovation Park, Chapelizod, Dublin D20 FX72, Ireland | [Phone / Email] | |
| Dr. Niamh Tierney | Vice President, Regulatory Affairs | Dublin HQ | [Phone / Email] | |
| Dr. Aisling Burke | Chief Technology Officer | Dublin HQ | [Phone / Email] | |
| Fiona Drennan | Director, Quality Assurance | Dublin HQ | [Phone / Email] | |
| Name | Title | Location | Contact | |
| Marcus Hale | Vice President, U.S. Operations | 220 Westbrook Drive, Suite 400, Cambridge, MA 02142 | [Phone / Email] | |
| Name | Title | Location | Contact | |
| Dr. Sandra Ellison | Managing Director | 9500 Medical Center Drive, Suite 210, Rockville, MD 20850 | [Phone / Email] | |
| Thomas Greenbaum | Senior Regulatory Specialist | Rockville, MD | [Phone / Email] | |
| Name | Title | Location | Contact | |
| Dr. Raymond Cho | Patent Attorney | 75 Federal Street, Suite 1800, Boston, MA 02110 | [Phone / Email] | |
| Name | Title | Location | Contact | |
| Dr. James Haverford | Director, Biocompatibility Testing | 1625 Shady Grove Road, Suite 300, Gaithersburg, MD 20878 | [Phone / Email] | |
| Name | Title | Location | Contact | |
| Dr. Lisa Fontaine | Vice President, Clinical Operations | 500 North Capitol Street, Suite 700, Indianapolis, IN 46204 | [Phone / Email] | |
| Description | Details | |||
| IRB Registration No. | IRB-2019-04821 |
| Location | 3200 Bayshore Boulevard, Tampa, FL 33629 | ||||
| Contact | [Phone / Email] | ||||
| Name | Title | Location | Contact | ||
| Ciara Brennan | Partner | 38 Fitzwilliam Square East, Dublin D02 NH85, Ireland | [Phone / Email] | ||
| Name | Title / Role | Location | Details | ||
| Dr. Henrik Vogt | Lead Auditor | Berlin, Germany | Notified Body No. 0483; EU MDR CE Certificate MCA-2024-07319 issued September 12, 2024 | ||
| Description | Details | ||||
| Policy No. | AUP-PL-2024-00893 | ||||
| Coverage | $25M per occurrence / $50M aggregate | ||||
| Policy Expiration | September 30, 2025 | ||||
| Location | London, United Kingdom | ||||
| Name | Title | Location | Contact | ||
| Declan Murray | Audit Partner | Dublin, Ireland | [Phone / Email] | ||
| Risk ID | Description | Likelihood | Impact | Mitigation Strategy | Owner |
| R-001 | FDA rejection of proposed primary predicate (K211034, NovaSense GlucoTrack NX-500). FDA may determine that the NX-500 is not an appropriate predicate for the Lumina CGM System due to differences in technological characteristics, intended use, or performance. | Medium | High | Pre-Sub meeting specifically designed to confirm predicate acceptance prior to 510(k) submission. Contingency analysis of alternative predicates (including K230489 as primary and other cleared iCGM devices) is underway. Robust substantial equivalence argument to be developed in Pre-Sub package. | C&H (Calloway, Whitfield); Pinnacle (Ellison) |
| R-002 | FDA determination that PMA (rather than 510(k)) is required. FDA may determine that the Lumina CGM System raises new questions of safety and effectiveness that cannot be addressed through the 510(k) pathway, necessitating a premarket approval (PMA) application. | Low | Critical | Robust substantial equivalence argument based on predicate comparison. Pre-Sub engagement to obtain early FDA feedback on pathway appropriateness. iCGM special controls compliance to demonstrate adequate safety and effectiveness controls within the Class II framework. | C&H (Calloway); Pinnacle (Ellison) |
| R-003 | Clinical study delays beyond March 15, 2026 completion target. Enrollment challenges, site activation delays, subject dropout, adverse events, or protocol amendments may extend the clinical study beyond the planned six-month duration. | Medium | High | Early clinical site identification and activation (6 sites). Enrollment buffer built into study design (350 subjects with [percentage]% dropout assumption). Experienced CRO (Veltrano) with established clinical site network. Regular enrollment tracking and escalation protocol. | Veltrano CRO (Dr. Fontaine); SBI (Hale); C&H (Whitfield) |
| R-004 | Biocompatibility testing failures (especially PtIr-4G electrode coating). The Lumina C14 sensor's proprietary PtIr-4G electrode coating may fail one or more biocompatibility tests (e.g., cytotoxicity, sensitization), requiring material reformulation and retesting. | Low-Medium | High | Early risk assessment based on material characterization data. Whitmore Laboratories performing phased testing with interim results. Alternative electrode coating materials identified by SBD engineering team as contingency. Design-around development (Section 3.6) may also address material composition. | Whitmore (Dr. Haverford); SBD (Dr. Burke, Drennan); C&H (Morrissey) |
| R-005 | FTO risk regarding NovaSense U.S. Patent No. 10,847,221. Crestline's preliminary assessment identifies a low-to-moderate risk of infringement based on enzyme coating structural similarities with the PtIr-4G technology. A formal assertion or litigation by NovaSense could disrupt the regulatory program and commercial launch. | Low-Medium | High | Design-around in progress (alternative electrode deposition process). Crestline claim chart analysis to provide definitive FTO assessment. Monitoring of NovaSense patent portfolio and enforcement activities. No formal dispute or litigation at present. | Crestline (Dr. Cho); SBD (Dr. Burke); C&H (Calloway) |
| R-006 | Insurance coverage gap (Atlas policy expires September 30, 2025 during clinical study). The Atlas Underwriting Partners product liability policy (Policy No. AUP-PL-2024-00893, $25M/$50M) expires during the planned clinical study period. A lapse in coverage could violate clinical site agreement requirements, expose the Client to uninsured liability, and potentially halt clinical operations. | Low (if timely renewal pursued) | Critical | Timely initiation of policy renewal process (no later than August 1, 2025). Client to coordinate with Atlas Underwriting and broker. Ensure renewed policy coverage is adequate for clinical study and anticipated U.S. commercial launch. | SBI (Hale); SBD (Dr. Tierney); Broadleaf (Murray) |
| R-007 | FDA reclassification or change in special controls for iCGM devices. FDA may issue new guidance, proposed rules, or final orders that modify the classification, special controls, or performance criteria applicable to iCGM devices, potentially requiring changes to the Lumina CGM System's regulatory strategy or performance testing plan. | Low | Medium-High | Ongoing monitoring of FDA regulatory actions, Federal Register notices, guidance documents, and CDRH announcements. C&H maintains regulatory intelligence tracking for all relevant product codes and device classifications. Engagement with industry associations and FDA stakeholders as appropriate. | C&H (Morrissey, Whitfield); Pinnacle (Ellison) |
| R-008 | [Placeholder for additional risks identified during the reporting period.] | [Likelihood] | [Impact] | [Mitigation Strategy] | [Owner] |
| Term / Acronym | Definition | ||||
| 510(k) | Premarket Notification under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360(k)); a regulatory submission demonstrating that a medical device is substantially equivalent to a legally marketed predicate device. | ||||
| BLE | Bluetooth Low Energy; a wireless personal area network technology designed for low-power data transmission, used for communication between the Lumina C14 sensor and the Lumina R7 reader. |
| CDRH | Center for Devices and Radiological Health; the FDA center responsible for the regulation of medical devices. |
| CGM | Continuous Glucose Monitoring; a method of tracking glucose levels in real time throughout the day and night via a sensor inserted under the skin. |
| CRO | Contract Research Organization (also Clinical Research Organization); a third-party organization that provides clinical trial management and related services to sponsors. |
| EMC | Electromagnetic Compatibility; the ability of a device to function properly in its electromagnetic environment without introducing intolerable electromagnetic disturbances to other devices. |
| FTO | Freedom-to-Operate; an analysis assessing whether a product, process, or service may be commercialized without infringing valid intellectual property rights held by third parties. |
| iCGM | Integrated Continuous Glucose Monitoring; a classification of CGM systems that meet specific accuracy and reliability criteria established by FDA, allowing integration with other compatible medical devices and electronic interfaces. |
| IDE | Investigational Device Exemption; an FDA authorization that allows an investigational device to be used in a clinical study to |